Internal Medicine, Hematology & Oncology · Fountain Valley, CA
NPI
1811384001
Since 2015
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
11180 Warner Ave Ste 351
Fountain Valley, CA, 92708
Phone (714) 698-0300
Groups this clinician bills Medicare through
Medicare paid, 2024
$245K
7,946 services
Medicare patients, 2024
189
Average age 74
Drug cost, 2024
$2.8M
885 prescriptions
Company payments, 2025
$8,082
From 58 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kevin DO was code 99214 (office e&m - established), 161 times for 88 patients. In total Kevin DO billed 7,946 services in 53 codes, and Medicare paid $245K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-12-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 161 | 88 | $96.21 | $15K |
| 99233 Hospital E&M - Subsequent | Facility | 135 | 50 | $96.54 | $13K |
| 99215 Office E&M - Established | Office | 131 | 58 | $147.94 | $19K |
| 36415 Venipuncture Blood Collection | Office | 69 | 45 | $8.60 | $594 |
| 99291 Critical Care E&M | Facility | 41 | 13 | $172.90 | $7,089 |
| 96127 Behavioral Health Services | Office | 37 | 36 | $3.99 | $148 |
| 96413 Chemotherapy Administration | Office | 33 | 11 | $105.36 | $3,477 |
| 99223 Hospital E&M - Initial | Facility | 30 | 30 | $141.85 | $4,256 |
| 99204 Office E&M - New | Office | 20 | 20 | $102.82 | $2,056 |
| 99205 Office E&M - New | Office | 13 | 13 | $173.12 | $2,251 |
By year: 2022 $248K for 12,770 services; 2023 $447K for 16,880 services; 2024 $245K for 7,946 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 69 | 45 | $8.60 | $594 |
Medicare prescription drug claims, 2024
In 2024, the drug Kevin DO prescribed most often to Medicare patients was Letrozole, with 46 prescriptions and refills. In total Kevin DO wrote 885 Medicare prescriptions that cost $2.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 46 | 133 | 17 | $969 |
| Dexamethasone Sodium Phosphate Generic | 37 | 38 | 11 | $148 |
| Diphenhydramine Hcl Generic | 34 | 34 | 11 | $90.98 |
| Tagrisso Osimertinib Mesylate | 31 | 31 | Under 11 | $533K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 27 | 29 | Under 11 | $634 |
| Prednisone Generic | 27 | 31 | Under 11 | $79.97 |
| Leucovorin Calcium Generic | 24 | 25 | Under 11 | $3,544 |
| Fluorouracil Generic | 22 | 22 | Under 11 | $1,285 |
| Lupron Depot Leuprolide Acetate | 21 | 59 | Under 11 | $122K |
| Dexamethasone Generic | 21 | 23 | Under 11 | $360 |
| Ondansetron Hcl Ondansetron Hcl/Pf | 21 | 22 | Under 11 | $67.58 |
| Hydroxyurea Generic | 20 | 33 | Under 11 | $351 |
| Loperamide Loperamide Hcl | 20 | 22 | 14 | $291 |
| Verzenio Abemaciclib | 19 | 19 | Under 11 | $282K |
| Famotidine Famotidine/Pf | 18 | 18 | Under 11 | $25.21 |
Brand drugs: 256 claims; generic drugs: 629 claims; opioid claims: 43.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kevin DO $8,082 ($8,082 in general payments such as food, travel and fees) from 58 companies. The largest payer was Novartis Pharmaceuticals Corporation with $1,168.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 23 | $1,168 |
| Janssen Biotech, Inc. JNJ | 16 | $486 |
| AstraZeneca Pharmaceuticals LP AZN | 18 | $456 |
| Merck Sharp & Dohme LLC MRK | 14 | $407 |
| Merz North America, Inc. | 4 | $309 |
| Regeneron Healthcare Solutions, Inc. REGN | 9 | $276 |
| GlaxoSmithKline, LLC. GSK | 13 | $248 |
| Celgene Corporation BMY | 12 | $231 |
| Abbvie Inc. ABBV | 16 | $230 |
| Exelixis Inc. EXEL | 8 | $224 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.